文献速递静脉血栓栓塞慢性静脉疾病

静脉造影分类及静脉胸廓出口综合征所致腋-锁骨下静脉血栓形成(Paget-Schroetter综合征)的长期手术治疗结局

Venographic classification and long-term surgical treatment outcomes for axillary-subclavian vein thrombosis due to venous thoracic outlet syndrome (Paget-Schroetter syndrome).
PubMed 文献 · J Vasc Surg · 2022-11-26

该回顾性单中心研究纳入2016至2022年接受初次手术治疗的266例静脉胸廓出口综合征所致腋-锁骨下静脉血栓形成患者,按术中静脉造影分为四组比较结局。中位随访38.7个月时93%患者无手臂肿胀,术中腋-锁骨下静脉通畅者95%无手臂肿胀 vs 长期慢性闭塞者69%(P < .001)。初始诊断时行导管导向溶栓者需静脉重建的可能性降低32%(30% vs 44%;P = .034)。

要点

  • 中位随访38.7个月时246例(93%)无手臂肿胀,仅17例(6%)接受抗凝治疗。
  • 术中腋-锁骨下静脉通畅者95%无手臂肿胀 vs 长期慢性闭塞者69%(P < .001)。
  • 初始诊断时行导管导向溶栓者需静脉重建可能性降低32%(30% vs 44%;P = .034)。

核心结论

  • 经锁骨周围胸廓出口减压、外膜静脉松解及依据术中静脉造影选择性的腋-锁骨下静脉重建可为超过90%的静脉胸廓出口综合征患者提供成功且持久的治疗。
  • 作者认为需进一步工作以实现腋-锁骨下静脉血栓形成的更早识别、及时使用导管导向溶栓及更有效的手术治疗。

研究设计与样本

  • 回顾性单中心研究,纳入2016至2022年间接受初次手术治疗的266例静脉胸廓出口综合征所致腋-锁骨下静脉血栓形成患者。
  • 根据术中静脉造影结果将患者分为四组比较临床结局。

主要发现

  • 266例中男性132例、女性134例,均有自发性手臂肿胀及特发性腋-锁骨下静脉血栓形成病史,其中25例(9%)证实有肺栓塞,平均年龄32.1 ± 0.8岁(范围12-66岁)。
  • 就诊时机为急性(<15天)132例(50%)、亚急性(15-90天)71例(27%)、慢性(>90天)63例(24%)。
  • 188例(71%)曾行静脉造影联合导管导向溶栓或血栓清除术和/或球囊血管成形术;症状发作至手术的中位间隔为78天。
  • 经锁骨周围胸廓出口减压及外膜静脉松解后,术中静脉造影显示150例(56%)腋-锁骨下静脉广泛通畅,26例(10%)存在长段慢性腋-锁骨下静脉闭塞且腋静脉流入不足以行旁路重建,55例(21%)因局限性狭窄行补片血管成形术,35例(13%)因节段性闭塞行旁路移植重建。
  • 仅行外膜静脉松解者(腋-锁骨下静脉通畅或闭塞;n = 176)较行腋-锁骨下静脉重建者(补片或旁路;n = 90)平均手术时间更短、术后住院时间更短、再手术及晚期再干预更少,总体并发症发生率或30天再入院率无差异。

临床怎么用

  • 作者认为经锁骨周围减压、外膜静脉松解及依据术中静脉造影选择性的腋-锁骨下静脉重建可为超过90%的静脉胸廓出口综合征患者提供成功且持久的治疗。
  • 作者认为需进一步工作以实现腋-锁骨下静脉血栓形成的更早识别、及时使用导管导向溶栓及更有效的手术治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed the clinical presentation, operative findings, and surgical treatment outcomes for axillary-subclavian vein (AxSCV) thrombosis due to venous thoracic outlet syndrome (VTOS). METHODS: We performed a retrospective, single-center review of 266 patients who had undergone primary surgical treatment of VTOS between 2016 and 2022. The clinical outcomes were compared between the patients in four treatment groups determined by intraoperative venography. RESULTS: Of the 266 patients, 132 were male and 134 were female. All patients had a history of spontaneous arm swelling and idiopathic AxSCV thrombosis, including 25 (9%) with proven pulmonary embolism, at a mean age of 32.1 ± 0.8 years (range, 12-66 years). The timing of clinical presentation was acute (<15 days) for 132 patients (50%), subacute (15-90 days) for 71 (27%), and chronic (>90 days) for 63 patients (24%). Venography with catheter-directed thrombolysis or thrombectomy (CDT) and/or balloon angioplasty had been performed in 188 patients (71%). The median interval between symptom onset and surgery was 78 days. After paraclavicular thoracic outlet decompression and external venolysis, intraoperative venography showed a widely patent AxSCV in 150 patients (56%). However, 26 (10%) had a long chronic AxSCV occlusion with axillary vein inflow insufficient for bypass reconstruction. Patch angioplasty was performed for focal AxSCV stenosis in 55 patients (21%) and bypass graft reconstruction for segmental AxSCV occlusion in 35 (13%). The patients who underwent external venolysis alone (patent or occluded AxSCV; n = 176) had a shorter mean operative time, shorter postoperative length of stay and fewer reoperations and late reinterventions compared with those who underwent AxSCV reconstruction (patch or bypass; n = 90), with no differences in the incidence of overall complications or 30-day readmissions. At a median clinical follow-up of 38.7 months, 246 patients (93%) had no arm swelling, and only 17 (6%) were receiving anticoagulation treatment; 95% of those with a patent AxSCV at the end of surgery were free of arm swelling vs 69% of those with a long chronic AxSCV occlusion (P < .001). The patients who had undergone CDT at the initial diagnosis were 32% less likely to need AxSCV reconstruction at surgery (30% vs 44%; P = .034) and 60% less likely to have arm swelling at follow-up (5% vs 13%; P < .05) vs those who had not undergone CDT. CONCLUSIONS: Paraclavicular decompression, external venolysis, and selective AxSCV reconstruction determined by intraoperative venography findings can provide successful and durable treatment for >90% of all patients with VTOS. Further work is needed to achieve earlier recognition of AxSCV thrombosis, prompt usage of CDT, and even more effective surgical treatment.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dadashzadeh ER, Ohman JW, Kavali PK, et al. Venographic classification and long-term surgical treatment outcomes for axillary-subclavian vein thrombosis due to venous thoracic outlet syndrome (Paget-Schroetter syndrome). J Vasc Surg. 2022. PMID: 36442701. doi:10.1016/j.jvs.2022.11.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。